Valuation estimate, page-66

Fairly conservative estimate for the remainder of May / June yrs 19/20 IMHO but agree and will be surprised if not greater. BOA for various reasons continuing to buy up to $3 mark. Share price indicates a steep growth curve and anticipate demand to drive growth through 20/21 and 21/22 from various areas of B2B & B2C and Apiam health along new swine flu emerging. Zoono is emerging as a must have.... the NO 1 to combat all the various microbiological bugs. Talk of 15-20 mill p/M while premature MAYBE!!!!!!!! ........ would not surprise given all the anecdotal evidence of companies using ZNO on various forums and on HC through the hard work of posters.

Long term holder and have enjoyed and complimented PH and his team before on their hard efforts.

GLTAH and DYOR.